MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...
Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
A chemical engineering professor at the University of Cincinnati is developing new ways to deliver treatments for infectious ...
Moderna's study looked at the vaccine in adults aged 50 and older, while Pfizer/BioNTech's trial focused on adults aged 18 to 64. Other rivals, meanwhile, include Sanofi/Novavax, which are ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback